Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9821731 | 0.85 | MEN1 (0.37) | PRCPMEN1GAAKMT2ACHRNB4 | |
| SCHEMBL18792440 | 0.85 | MEN1 (0.33) | PRCPMEN1GAAKMT2ACHRNB4 | |
| SCHEMBL18886228 | 0.85 | MEN1 (0.33) | PRCPMEN1GAAKMT2ACHRNB4 | |
| SCHEMBL31377463 | 0.82 | ADRA2B (0.32) | PRCPMEN1GAAKMT2APAX8 | |
| SCHEMBL24090522 | 0.81 | AR (0.40) | PRCP | |
| SCHEMBL13059131 | 0.81 | AR (0.40) | PRCP | |
| SCHEMBL18886131 | 0.81 | AR (0.40) | PRCP | |
| SCHEMBL1615703 | 0.76 | CDC7 (0.38) | CHRNB4CHRNA3CDC7 | |
| SCHEMBL22603159 | 0.76 | CYP1A2 (0.38) | PRMT5WDR77 | |
| SCHEMBL23372989 | 0.76 | HTR2A (0.32) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-3322417-B1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | UNIV TEXAS (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20070003680-A1 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TRANSTECH PHARMA, LLC | 2005-08-04 | — | — | US | disclosed |
| US-5322951-A | Antiserotine agent | BEECHAM GROUP, P.L.C. (GB) | 1994-06-21 | — | — | US | disclosed |
| US-5200413-A | Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis | BEECHAM GROUP P.L.C. (GB) | 1993-04-06 | — | — | US | disclosed |
| US-5049556-A | Certain N-azabicyclo-2,3-dihydro-indole-1-carboxamides having anti-emetic properties, further found useful in treating headaches, neuralgia and anxiety | BEECHAM GROUP P.L.C. (GB) | 1991-09-17 | — | — | US | disclosed |
| EP-0363466-A1 | NOVEL COMPOUNDS | BEECHAM GROUP PLC (GB) | 1990-04-18 | — | — | EP | disclosed |
| WO-1989009217-A1 | NOVEL COMPOUNDS | BEECHAM GROUP PLC (GB) | 1989-10-05 | — | — | WO | disclosed |
| US-4871744-A | TREATMENT OF ANXIETY, PSYCHOSIS, MIGRAINS | BEECHAM GROUP P.L.C. (GB) | 1989-10-03 | — | — | US | disclosed |
| US-4159271-A | CYCLIZATION OF A 2-HALOGENOPHENETHYLAMINE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-06-26 | — | — | US | disclosed |
| US-3935199-A | ANALEPTIC | MEAD JOHNSON & COMPANY (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | PRCP 1167/4885MEN1 2469/4885GAA 1798/4885 |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, WEE1, SHBG | PRCP 2243/4885MEN1 988/4885GAA 2655/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | PRCP 412/4885MEN1 2589/4885GAA 234/4885 |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | PRCP 1034/4885MEN1 1418/4885GAA 3182/4885 |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TFPI, F3, F2 | PRCP 132/4885MEN1 3900/4885GAA 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.